Drug reps and the academic medical center: A case for management rather than prohibition

Perspectives in Biology and Medicine

Volumn 51, Issue 2, 2008, Pages 251-260

  Huddle, Thomas S ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFLICT OF INTEREST; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; GIFT GIVING; HUMAN; MEDICAL PRACTICE; PHYSICIAN; PRIORITY JOURNAL; REVIEW; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ATTITUDE OF HEALTH PERSONNEL; CONFLICT OF INTEREST; DRUG INDUSTRY; EDUCATION, MEDICAL; GIFT GIVING; HUMANS; MARKETING;

EID: 43449110747     PISSN: 00315982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Azoulay, P. 2002. Do pharmaceutical sales respond to scientific evidence? J Econ Man Strat 11(4):551-94.
2. Bates v. State Bar of Arizona, 433 U.S. 350, 97 S.Ct. 2691 (1977).
3. Berenson, A. 2007. Lilly settles with 18,000 over Zyprexa. NY Times (Jan. 5).
4. Bower, A. D., and G. L. Burkett. 1987. Family physicians and generic drugs. J Fam Prac 24(6):612-16.
5. Bowman, M. A., and D. L. Pearle. 1988. Changes in drug prescribing paterns related to commercial company funding of continuing medical education. J Cont Ed Health Prof 8(1):13-20.
6. Brennan, T. A., et al. 2006. Health industry practices that create conflicts of interest: A proposal for academic medical centers. JAMA 295(4):429-33.
7. Carson, T. L. 2004. Conflicts of interest and self-dealing in the professions: A review essay. Bus Ethics Q 14(1):161-82.
8. Caudill, T. S., et al. 1996. Physicians, pharmaceutical sales representatives and the cost of prescribing. Arch Fam Med 5(4):201-6.
9. Chimonas, S., T. A. Brennan, and D. J. Rothman. 2007. Physicians and drug representatives: Exploring the dynamics of the relationship. J Gen Intern Med 22:184-90.
10. Davis, M., and A. Stark. 2001. Conflict of interest in the professions. New York: Oxford Univ. Press.
11. Epstein, R. A. 2007. Conflicts of interest in health care: Who guards the guardians? Perspect Biol Med 50(1):72-88.
12. Gonul, F. F., et al. 2001. Promotion of prescription drugs and its impact on physicians' choice behavior. J Marketing 65(July):79-90.
13. Goodman, R. L. 2007. Medical education and the pharmaceutical industry. Perspect Biol Med 50(1):32-39.
14. Hrachovec, J. B., and M. Mora. 2001. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib [letter]. JAMA 286:2398
15. Ioannidis, J. P. 2005. Molecular bias. Eur J Epidemiol 20:739-45.
16. Johanson, H. K., and P. C. Gotzsche. 1999. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 282:1752-59.
17. Katz, D., A. L. Caplan, and J. F. Merz. 2003. All gifts large and small: Toward an understanding of pharmaceutical industry gift-giving. Am J Bioeth 3(3):40-46.
18. Latham, S. R. 2001. Conflicts of interest in medical practice. In Conflict of interest in the professions, ed. M. Davis and A. Stark; 279-301. Oxford: Oxford Univ. Press.
19. Lichtenberg, F. 2005. The impact of new drug launches on longevity: Evidence from longitudinal, disease-level data from 52 countries, 1982-2001. Int J Health Care Finance Econ 5:47-73.
20. Manchanda, P. 2004. Responsiveness of physician prescription behavior to salesforce effort: An individual level analysis. Marketing Lett 15(2-3):129-45.
21. Manchanda, P., and E. Honka. 2005. The effects and role of direct-to-physician marketing in the pharmaceutical industry: An integrative review. Yale J Health Pol Law Ethics 5(2):785-822.
22. Manchanda, P., Y. Xie, and N. Youn. 2004. The role of targeted communication and contagion in product adoption. University of Chicago working paper. http://www.olin.wustl.edu/fs/acadseminars/downloadPDF.cfm?recNum=41627.
23. McCormick, B. B., et al. 2001. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on post-training attitudes and behavior. JAMA 286(16):1994-99.
24. Mizik, N., and R. Jacobson. 2004. Are physicians "easy marks"? Quantifying the effects of detailing and sampling on new prescriptions. Manag Sci 50(12):1704-15.
25. Morgan, P. W., and G. H. Reynolds. 1997. The appearance of impropriety: How ethics wars have undermined American government, business and society. New York: Free Press.
26. Narayanan, S., R. Desiraju, and P. K. Chintagunta. 2004. Return on investment implications for pharmaceutical promotional expenditures: The role of marketing-mix interactions. J Marketing 68(Oct.): 90-105.
27. Narayanan, S., P. Manchanda, and P. Chintagunta. 2003. The informative versus persuasive role of marketing communication in new product categories: An application to the prescription antihistamines market. (Sept. 3). SSRN: http://ssrn.com/abstract=472881 or DOI: 10.2139/ssrn.472881.
28. Pharmaceutical Research and Manufacturers of America (PhRMA). 2004. PhRMA code on interactions with healthcare professionals. http://www.phrma.org/ code_on_interactions_with_healthcare_professionals/.
29. Rizzo, J. A. 1999. Advertising and competition in the ethical pharmaceutical industry: The case of anti-hypertensive drugs. J Law Econ 42(April):89-116.
30. Rubin, P. H. 2004. Pharmaceutical marketing: Medical and industry biases. J Pharm Fin Econ Pol 13(2):65-79.
31. Spingarn, R. W., J. A. Berlin, and B. L. Strom. 1996. When pharmaceutical manufacturers' employees present grand rounds, what do residents remember? Acad Med 71(1):86-88.
32. Steinman, M. A., et al. 2006. Narrative review: The promotion of gabapentin: An analysis of internal industry documents. Ann Intern Med 145:284-93.
33. Stelfox, H. T., et al. 1998. Conflict of interest in the debate over calcium-channel antagonists. New Engl J Med 338(2):101-6.
34. Wazana, A. 2000. Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA 283(3):373-80.
35. Windmeijer, F. E., et al. 2006. Pharmaceutical promotion and GP prescription behavior. Health Econ 15:5-18.